Pharmacokinetics of single dose intravenous XXXX in neonates: effect of gestational age.

@entity1 @entity11622 @entity158 @entity230 @entity1443
AIM: To investigate the pharmacokinetics and pharmacodynamics of single dose @entity11622 in preterm and term @entity1 on the first day of life. METHODS: Neonates were stratified by gestational age. Preterm (< 37 weeks) and term (37-41 weeks) @entity1 received a single dose of @entity11622 in the first 24 hours of life when they had minor, painful procedures or as additional treatment in @entity1 receiving opioids. Blood samples were taken from an arterial line, and @entity158 was evaluated by a multidimensional @entity158 scale. Results were reported as mean (SD). Student's t and Wilcoxon tests were used to compare the groups. RESULTS: Thirty neonates were included, 10 of which were term infants. Serum half life was 277 (143) minutes in the preterm @entity1 and 172 (59) minutes in the term @entity1 (p < 0.05). Clearance was 0.116 (0.08) litre/kg/h in the preterm @entity1 and 0.170 (0.06) litre/kg/h in the term @entity1 (p < 0.05). Gestational age correlated with serum half life (r = -0.46). No effect of sex or administration of prenatal @entity230 was found on the pharmacokinetics of @entity1443 . In neonates who only received @entity11622 (n = 15), the level of analgesia seemed to be associated with the therapeutic (> 5 mg/l) level. CONCLUSIONS: A correlation was found between gestational age and the serum half life of @entity11622 . The maturational trend of clearance and half life in preterm and term neonates is in line with data on the pharmacokinetics of @entity11622 beyond the newborn period.
